495 related articles for article (PubMed ID: 31632004)
1. Pharmacokinetic studies of nanoparticles as a delivery system for conventional drugs and herb-derived compounds for cancer therapy: a systematic review.
Abdifetah O; Na-Bangchang K
Int J Nanomedicine; 2019; 14():5659-5677. PubMed ID: 31632004
[TBL] [Abstract][Full Text] [Related]
2. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review.
Muhamad N; Plengsuriyakarn T; Na-Bangchang K
Int J Nanomedicine; 2018; 13():3921-3935. PubMed ID: 30013345
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interactions between herbal medicines and prescribed drugs: focus on drug metabolic enzymes and transporters.
Meng Q; Liu K
Curr Drug Metab; 2014; 15(8):791-807. PubMed ID: 25705905
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Drug Metabolism Studies of Plants With Anticancer Properties: Approaches Applied and Limitations.
Thiengsusuk A; Boonprasert K; Na-Bangchang K
Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):173-225. PubMed ID: 31679146
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles as delivery carriers for anticancer prodrugs.
Fang JY; Al-Suwayeh SA
Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
[TBL] [Abstract][Full Text] [Related]
7. Nanocarriers for cancer-targeted drug delivery.
Kumari P; Ghosh B; Biswas S
J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
[TBL] [Abstract][Full Text] [Related]
8. Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo Evidence.
Santos AC; Pereira I; Magalhães M; Pereira-Silva M; Caldas M; Ferreira L; Figueiras A; Ribeiro AJ; Veiga F
AAPS J; 2019 Apr; 21(4):57. PubMed ID: 31016543
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.
Farooq MA; Aquib M; Khan DH; Hussain Z; Ahsan A; Baig MMFA; Wande DP; Ahmad MM; Ahsan HM; Jiajie J; Wang B
Daru; 2019 Dec; 27(2):853-862. PubMed ID: 31758497
[TBL] [Abstract][Full Text] [Related]
10. Solid Matrix Based Lipidic Nanoparticles in Oral Cancer Chemotherapy: Applications and Pharmacokinetics.
Ahmad J; Amin S; Rahman M; Rub RA; Singhal M; Ahmad MZ; Rahman Z; Addo RT; Ahmad FJ; Mushtaq G; Kamal MA; Akhter S
Curr Drug Metab; 2015; 16(8):633-44. PubMed ID: 26264206
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Consequences of PLGA Nanoparticles in Docetaxel Drug Delivery.
Rafiei P; Haddadi A
Pharm Nanotechnol; 2017; 5(1):3-23. PubMed ID: 28948907
[TBL] [Abstract][Full Text] [Related]
12. Metabolite Profiling in Anticancer Drug Development: A Systematic Review.
Muhamad N; Na-Bangchang K
Drug Des Devel Ther; 2020; 14():1401-1444. PubMed ID: 32308372
[TBL] [Abstract][Full Text] [Related]
13. Delivery of anticancer drugs.
Zee-Cheng RK; Cheng CC
Methods Find Exp Clin Pharmacol; 1989; 11(7-8):439-529. PubMed ID: 2689812
[TBL] [Abstract][Full Text] [Related]
14. Effects of Zeolite as a Drug Delivery System on Cancer Therapy: A Systematic Review.
Hao J; Stavljenić Milašin I; Batu Eken Z; Mravak-Stipetic M; Pavelić K; Ozer F
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684777
[TBL] [Abstract][Full Text] [Related]
15. Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance.
Saneja A; Khare V; Alam N; Dubey RD; Gupta PN
Expert Opin Drug Deliv; 2014 Jan; 11(1):121-38. PubMed ID: 24295039
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic comparisons by UPLC-MS/MS of isomer paeoniflorin and albiflorin after oral administration decoctions of single-herb Radix Paeoniae Alba and Zengmian Yiliu prescription to rats.
Gong C; Yang H; Wei H; Qi C; Wang CH
Biomed Chromatogr; 2015 Mar; 29(3):416-24. PubMed ID: 25042570
[TBL] [Abstract][Full Text] [Related]
17. Adaptive control methods for the dose individualisation of anticancer agents.
Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers.
Aljuffali IA; Fang CL; Chen CH; Fang JY
Curr Pharm Des; 2016; 22(27):4219-31. PubMed ID: 27323758
[TBL] [Abstract][Full Text] [Related]
19. Improved pharmacokinetic profile of lipophilic anti-cancer drugs using ανβ3-targeted polyurethane-polyurea nanoparticles.
Rocas P; Fernández Y; García-Aranda N; Foradada L; Calvo P; Avilés P; Guillén MJ; Schwartz S; Rocas J; Albericio F; Abasolo I
Nanomedicine; 2018 Feb; 14(2):257-267. PubMed ID: 29127040
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic profiles of anticancer herbal medicines in humans and the clinical implications.
Chen XW; Sneed KB; Zhou SF
Curr Med Chem; 2011; 18(21):3190-210. PubMed ID: 21671861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
